Yearly Archives: 2024

Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:1. Development Update on the Ocumetics IOL2. Remaining steps to first-in-human study3. Q&A session Thanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in

Dear Stakeholders,I want to take a moment to update you on our progress with the development of Ocumetics’ accommodative intraocular lens (AIOL), which will soon undergo its first-in-human (FIH) trials.As you know, we are committed to pioneering advanced ophthalmic technologies that will transform the way we treat cataracts and other vision conditions. In recent internal

Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:Successful manufacture of the Ocumetics IOLRemaining steps to first-in-human studyQ&A sessionThanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!https://youtu.be/U0GrNVtLNSc?si=lZYKlYUM2tH-KDjJ

Dear Shareholders, Partners, and Visionaries, I am thrilled to share a ground-breaking development from Ocumetics Technology Corp. that marks a monumental step forward in the world of vision enhancement. Today, I am pleased to announce the successful manufacture of our accommodating intraocular lens (IOL) designed to respond to the natural muscle activity of the human

Ocumetics Director and CEO, Dean Burns, walks through relevant topics including:Manufacturing of the Ocumetics IOLJourney to first-in-human studyQ&A sessionThanks to everyone who joined us for the Webinar. It was an amazing turnout, and it was great to hear your questions and comments. We look forward to hosting more webinars in the future!https://youtu.be/4zxDK3kSSYE?si=omXiuekk30ZBqHgn

Dear Ocumetics Team, Partners and Stakeholders,I am thrilled to share an exciting update in our journey to revolutionize vision correction technology. Last week, we proudly announced, in a separate press release, the commencement of manufacturing for the Ocumetics accommodating intraocular lens (IOL). This is not just a milestone for our corporation, but a significant leap

Ocumetics Announces Completion of First Tranche of Debenture Private Placement for Net Proceeds of CA$2.82 Million Dear Ocumetics Investors,  I am thrilled to share some exciting news that marks a significant milestone for our company and our mission to revolutionize eye care technology. I am pleased to announce that Ocumetics has successfully closed the first